Candidiasis - 83 Studies Found

Completed : Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
: Recurrent Vulvovaginal Candidiasis
: 2010-02-10
:
  • Biological: PEV7C1 capsule int
Completed : Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
: Vulvovaginal Candidiasis
: 2010-06-09
:
  • Drug: arasertaconazole nitrate

Completed : A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
: Vulvovaginal Candidiasis
: 2009-12-23
:
  • Drug: Butoconazole Nitrate Vaginal Cream

Completed : ProF-001_Phase IIa
: Vulvovaginal Candidiasis (VVC)
: 2017-03-13
:
  • Drug: Candiplus Administration
Active, not recruiting : A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
: Recurrent Vulvovaginal Candidiasis
: 2014-10-08
:
  • Drug: VT-1161
  • Drug: Placebo
Completed : Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
:
  • Systemic Aspergillosis
  • Systemic Candidiasis

: 2009-12-28
Completed : Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
:
: 2025-09-06
: This is not an interventional study
Completed : Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
:
: 2025-09-06
: Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per
Completed : Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
: 2025-09-06
: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who ha
NOT_YET_RECRUITING : Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
: Candidiasis, Oral
: 2025-09-06
: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days.The intervention soluti
<<< Previous | Next >>>